- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Lurasidone drug-drug interaction studies: a comprehensive review ; volume:29 ; number:3 ; year:2014 ; pages:191-202 ; extent:12
Drug metabolism and drug interactions ; 29, Heft 3 (2014), 191-202 (gesamt 12)
- Urheber
-
Chiu, Yu-Yuan
Ereshefsky, Larry
Preskorn, Sheldon H.
Poola, Nagaraju
Loebel, Antony
- DOI
-
10.1515/dmdi-2014-0005
- URN
-
urn:nbn:de:101:1-2411251643082.820823609637
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:36 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chiu, Yu-Yuan
- Ereshefsky, Larry
- Preskorn, Sheldon H.
- Poola, Nagaraju
- Loebel, Antony
Ähnliche Objekte (12)
Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies
Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Case report: Medical cannabis—warfarin drug-drug interaction
Evaluating drug-drug interaction information in NDF-RT and DrugBank
Evaluation of a drug-drug interaction: fax alert intervention program
Learning self-supervised molecular representations for drug–drug interaction prediction
On the robustness of generalization of drug–drug interaction models
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Comprehensive in vitro analysis evaluating the variable drug–drug interaction risk of rifampicin compared to rifabutin
Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels
Targeting continuity of care and polypharmacy to reduce drug–drug interaction
Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies
Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Case report: Medical cannabis—warfarin drug-drug interaction
Evaluating drug-drug interaction information in NDF-RT and DrugBank
Evaluation of a drug-drug interaction: fax alert intervention program
Learning self-supervised molecular representations for drug–drug interaction prediction
On the robustness of generalization of drug–drug interaction models
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Comprehensive in vitro analysis evaluating the variable drug–drug interaction risk of rifampicin compared to rifabutin
Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels
Targeting continuity of care and polypharmacy to reduce drug–drug interaction
Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies
Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Case report: Medical cannabis—warfarin drug-drug interaction
Evaluating drug-drug interaction information in NDF-RT and DrugBank
Evaluation of a drug-drug interaction: fax alert intervention program
Learning self-supervised molecular representations for drug–drug interaction prediction
On the robustness of generalization of drug–drug interaction models
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Comprehensive in vitro analysis evaluating the variable drug–drug interaction risk of rifampicin compared to rifabutin
Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels